Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

Table 5 Haematological adverse events n (%)

	All patients	Boceprevir	Telaprevir	P value	Non-F4	F4	P value
Neutropaenia	n = 943	n = 360	n = 583		n = 369	n = 505
Grade 0-1-2:	707 (75)	241 (67)	466 (80)	0	289 (78)	370 (73)	NS
> 750 μL
Grade 3-4:	236 (25)	119 (33)	117 (20)		80 (22)	135 (27)
≤ 750 μL
Thrombocytopaenia	n = 935	n = 359	n = 576		n = 365	n = 501
Grade 0-1-2:							0.000
> 50.000 μL	753 (81)	293 (82)	460 (80)	NS	337 (92)	371 (74)
Grade 3-4:
≤ 50.000 μL	182 (20)	66 (18)	116 (20)		28 (8)	130 (26)
Anaemia	n = 1036	n = 397	n = 639		n = 411	n = 539
Grade 0-1-2:	943 (91)	367 (92)	576 (90)	NS	384 (93)	481 (89)	0.025
> 8 g/dL
Grade 3-4:	93 (9)	30 (8)	63 (10)		27 (7)	58 (11)
< 8 g/dL
Transfusion	n = 1036	n = 397	n = 639	0.001	n = 411	n = 539	NS
	150 (15)	39 (10)	111 (17)		49 (12)	85 (16)
EPO	n = 1033	n = 396	n = 637	0	n = 410	n = 539	NS
	218 (21)	60 (15)	158 (25)		75 (18)	117 (22)
Onset of anaemia ( ≤ 9.5 g/dL)	12 ± 8	15 ± 11	9.5 ± 6.1	0	11.3 ± 7.2	11.5 ± 9	NS

n (%) and χ² tests summarise the categorical variables; mean ± SD and Student’s t-test. NS: Not significant.